MESOBLAST LTD (MESO) Form 20-F — Aug 27, 2026
Mesoblast filed its Form 20-F for fiscal 2026 (ended June 30, 2026), reporting $115.2 million of net product sales in its first full year of commercializing Ryoncil (remestemcel-L), the first mesenchymal stromal cell therapy approved by the FDA, together with a net loss of $57.5 million and accumulated losses of $1,068.4 million since inception. The company ended the year with $102.9 million in cash after using $43.8 million of operating cash during the period, and states that existing cash plus Ryoncil sales should fund forecast operating cash usage over the next twelve months.
Key figures
- Revenue
- 115200000
- Debt Amount
- 125000000
- Cash Position
- 102900000
- Interest Rate
- 8
- Maturity Date
- December 2030 (five-year facility entered December 2025)
- Shares Outstanding
- 1296862776
- Revenue note
- $115.2 million is FY2026 net product sales of Ryoncil, launched March 2025
- Credit facility
- $125.0 million five-year non-dilutive credit line secured by TEMCELL royalties, fully drawn in tranches of $75.0 million (December 2025) and $50.0 million (June 2026)
- Usd share of cash
- Approximately 98% of cash and cash equivalents denominated in U.S. dollars
- Credit facility use
- Proceeds used to extinguish prior debt with Oaktree Capital Management and NovaQuest Capital Management
- Accumulated losses since inception
- $1,068.4 million
- Net cash used in operations fy2026
- $43.8 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.